COMPANY
|
|
Definitive Distribution Agreement between Velos and Prostagen
San Francisco, CA and Allendale, NJ - March 5, 1999
- Velos, Inc. - San Francisco, CA and Prostagen Inc. Allendale, NJ -
announced today a definitive agreement to distribute Velos
disease management software and information products in the prostate
cancer market. Through the agreement, Velos becomes Prostagen's
disease management software arm, and Prostagen becomes Velos'
distribution and commercialization partner for Velos software and
information products for use in prostate cancer.
“This
agreement will help Velos rapidly penetrate the oncology market with
its exciting, process-centered paradigm for medical informatics, "
said John S. McIlwain, President of Velos Medical Informatics.
"Prostagen has close working relationships with several leading
urologists focused on prostate cancer care and research. By offering
one seamless system that supports clinical operations, patient
research, and clinical trials, we give our clinician/investigator
customers powerful advantages in efficiency and speed which can in
turn be of significant value to the governmental agencies,
pharmaceutical companies, and private organizations funding
research. This creates a nice three-way win for the clinicians and
their institutions, the sponsors, and ultimately the patient."
Students in the course are applying acquired skills and technologies
to:
According to Michael I. Sherman, President and CEO of
Prostagen Inc., “Each year in the United States, more than forty
thousand men die of prostate cancer and approximately two hundred
thousand men are newly diagnosed with the disease. These men are
heavily dependent on their care-giving team for guidance and
treatment. It is Prostagen’s objective to improve the ability of
healthcare professionals to satisfy those needs. An integrated
software system for managing prostate cancer patients could markedly
contribute to the effectiveness and efficiency of the care-giving
team. I believe that the software system developed by Velos offers
these important advantages. We at Prostagen look forward to working
with Velos to make the software widely available to those
individuals who treat prostate cancer patients.”
Velos
designs, develops and markets disease management software for the
renal disease/dialysis, transplantation, oncology, cardiology and
cardiothoracic surgery markets. Velos software encompasses patient
care, clinical outcomes, scheduling, clinical research, case
management, financial management and decision support. Velos
products are under contract in more than 1,000 clinics and
hospitals, including 90% of the cardiothoracic market, 50% of the
cardiology surgery market, 16% of the dialysis market, and are
becoming a rapidly growing presence in the transplantation and
oncology markets. Velos has fast become a market leader in specialty
and disease management medical informatics.
Prostagen has the
mission of improving the treatment and care of patients with
urogenital cancer. Among the key focus areas of the Company are
therapies involving PSMA, a prostate-specific protein widely
regarded as the ideal target for prostate cancer immunotherapy,
treatments to reduce pain associated with prostate cancer and
software to improve both the management of cancer patients and the
development of programs to predict which patients are most likely to
respond best to various treatment alternatives.
|
|
